Categories
Cardiovascular
Diagnostics
Endocrinology
Health Insurance
Medical Devices
Mental Health
Nutrition
Oncology
Public Health
Sexual Health
Popular Articles

Between 1992 And 2005 Survival Rates For Elderly Receiving Hospital CPR Did Not Improve
A study of elderly patients receiving CPR in the hospital shows that rates of survival did not improve from 1992 to 2005. During that period, the proportion of hospital deaths preceded by CPR rose, and the proportion of patients who were successfully resuscitated and later discharged home fell. The researchers found that 18.3 percent of the Medicare beneficiaries age 65 and older who underwent in-hospital CPR survived to discharge.
generic viagra online
Family Doctors Condemn Cuts To Funding, Northern Ireland
Commenting on the publication of the results of a national patient access survey today (Tuesday, 30 June 2009) local general practitioners expressed anger that a survey which shows how well general practice is delivering care to patients has resulted in the expected loss of up to ÷£2 million of funding for local GP services. For example, one practice in Northern Ireland with a list size of over 9,000 has lost all of its funding for patient access. Despite providing both 48 hour access and offering the option for patients to book ahead, the perception of just 3% of its patients has resulted in a loss of approximately ÷£15,000 in funding for services.
News of the day
St. Petersburg Times Examines Work Of Paul Farmer, Potential Candidate For USAID, State Department Position
The St. Petersburg Times examines the work of Paul Farmer - "the Harvard-educated doctor who, starting in Haiti, built a multinational organization on the radical idea that poor patients deserve the same care as rich ones" and is reportedly being considered for a high-level job with USAID or the State Department. The newspaper reports that though it"s "not a sure thing, even his candidacy indicates how far the international aid establishment has come around to Farmer"s way of thinking, health care experts say."
Diagnostics

FDA Designates Fast Track Status For Apaziquone (EOquin(R)) For Bladder Cancer

Spectrum Pharmaceuticals (NasdaqGM: SPPI) and Allergan, Inc. (NYSE:AGN) today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track Designation for the investigation of apaziquone (EOquin®) for the treatment of non-muscle invasive bladder cancer, a form of bladder cancer localized in the surface layers of the bladder that has not spread to the deeper muscle layer. Approximately 70% of all newly diagnosed patients with bladder cancer have non-muscle invasive bladder cancer.1 More than one million patients in the United States and Europe are estimated to be affected by the disease.2 "We are pleased that the FDA has accepted apaziquone under its Fast Track program," said Rajesh C. Shrotriya, MD, Chairman, President, and Chief Executive Officer of Spectrum Pharmaceuticals. "In a marker lesion study, where patients had previously failed multiple therapies, apaziquone produced a 67% complete response and was well-tolerated. We look forward to continuing with Phase 3 studies evaluating the efficacy and safety of apaziquone, while working with the FDA to expedite the drug"s development, review and approval process so we can help address the substantial unmet needs of patients suffering from non-muscle invasive bladder cancer." Fast Track designation is designed to facilitate drug development and expedite the review of drugs intended to treat serious conditions and demonstrate the potential to address unmet medical needs. The purpose is to get important new drugs to the patient earlier. Fast Track addresses a broad range of serious diseases. Once a drug receives Fast Track designation, early and frequent communication between the FDA and a drug company is encouraged throughout the entire drug development and review process. The frequency of communication facilitates the sponsor"s ability to expeditiously address questions and issues. A drug that receives Fast Track designation is eligible for a Rolling Review, which means that a drug company can submit completed sections of its New Drug Application (NDA) for review by FDA, rather than waiting until every section of the application is completed before the entire application can be reviewed. NDA review usually does not begin until the drug company has submitted the entire application to the FDA. About Spectrum Pharmaceuticals Spectrum Pharmaceuticals is a commercial-stage biotechnology company with a focus in oncology. The Company"s strategy is comprised of acquiring and developing a broad and diverse pipeline of late-stage clinical and commercial products; establishing a commercial organization for its approved drugs; continuing to build a team with people who have demonstrated skills, passion, commitment and have a track record of success in its areas of focus; and, leveraging the expertise of partners around the world to assist it in the execution of its strategy. For more information, please visit the Company"s website at http://www.spectrumpharm.com. Allergan, Inc.


Add your comment:
Name:
Site address: http://
Your message:
Enter today\\\\'s date, 2 digits
(spam protection):

© Copyright 2009